Continued Benefit, More Toxicity With Osimertinib-Chemo : vi

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.

Related Keywords

Netherlands , Peru , Lima , Amsterdam , Noord Holland , Natalia Isabel Valdiviezo Lama , Netherlands Cancer Institute , Drug Administration , National Institute Of Neoplastic Diseases , European Lung Cancer Congress , National Institute , Neoplastic Diseases , Medscape Medical News , Joop De Langen , Non Small Cell Lung Cancer , Nsclc , Lung Cancer , Ung Carcinoma , Ancer Of The Lung , Chemotherapy , Toxicology , Toxicity , Poisoning , Toxins , Platinum , Biologic Therapy , Iologics , Tyrosine Kinase Inhibitor , Rlotinib , Efitinib , Matinib , U11248 , Unitinib , Small Cell Lung Cancer , At Cell Lung Cancer , Clc , Metastasis , Etastatic Carcinoma , Metastatic Cancer , Metastases , Cancer ,